- /
- Supported exchanges
- / US
- / AIDX.NASDAQ
20/20 Biolabs, Inc. Common Stock (AIDX NASDAQ) stock market data APIs
20/20 Biolabs, Inc. Common Stock Financial Data Overview
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get 20/20 Biolabs, Inc. Common Stock data using free add-ons & libraries
Get 20/20 Biolabs, Inc. Common Stock Fundamental Data
20/20 Biolabs, Inc. Common Stock Fundamental data includes:
- Net Revenue: 2 043 K
- EBITDA: -3 138 820
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
20/20 Biolabs, Inc. Common Stock News
New
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: A...
20/20 BioLabs Secure U.S. License For Advanced CKD Prediction Technology
(RTTNews) - 20/20 BioLabs, Inc., (AIDX) is strengthening its position in the fast-growing longevity analytics space after securing an exclusive U.S. license to integrate ROKIT Healthcare's chronic kid...
How The Healwell AI (TSX:AIDX) Investment Story Is Shifting With Recut Targets And Growth Assumptions
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Healwell AI is back in focus after analysts trimmed fair value from CA$3.45 to CA$2.85, rou...
20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities
20/20 Biolabs Inc. Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health I...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.